Early-demographic dividend vs Rwanda: Immunization, Hib3
Early-demographic dividend
86.1%
in 2024
Rwanda
98.0%
in 2024
Early-demographic dividend rank
17th
Rwanda rank
20th
Immunization, Hib3 over time
- Early-demographic dividend
- Rwanda
How they compare
Rwanda currently reports 98.0% against 86.1% in Early-demographic dividend, a difference of 11.9%.
That makes Rwanda's figure about 1.1 times Early-demographic dividend's.
Across all 23 years both countries report, Rwanda has been ahead every year.
Early-demographic dividend ranks 17th and Rwanda ranks 20th of 43 groups.
Rwanda has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Early-demographic dividend | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 16.5% | 94.8% | 78.3% | Rwanda |
| 2010s | 61.9% | 97.7% | 35.8% | Rwanda |
| 2020s | 84.4% | 93.8% | 9.4% | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Early-demographic dividend or Rwanda?
- Rwanda, at 98.0% against 86.1% in Early-demographic dividend as of 2024.
- What is the difference in immunization, hib3 between Early-demographic dividend and Rwanda?
- 11.9%, with Rwanda ahead.
- How many years of comparable data are there for Early-demographic dividend and Rwanda?
- 23 years are reported by both, from 2002 to 2024.
- How do Early-demographic dividend and Rwanda rank globally for immunization, hib3?
- Early-demographic dividend ranks 17th and Rwanda ranks 20th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.